κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction

Addictions to cocaine or heroin/prescription opioids [short-acting μ-opioid receptor (MOPr) agonists] involve relapsing cycles, with experimentation/escalating use, withdrawal/abstinence, and relapse/re-escalation. κ-Opioid receptors (KOPr; encoded by OPRK1), and their endogenous agonists, the dynorphins (encoded by PDYN), have counter-modulatory effects on reward caused by cocaine or MOPr agonist exposure, and exhibit plasticity in addictive-like states. KOPr/dynorphin activation is implicated in depression/anxiety, often comorbid with addictions. In this opinion article we propose that particular stages of the addiction cycle are differentially affected by KOPr/dynorphin systems. Vulnerability and resilience can be due to pre-existing (e.g., genetic) factors, or epigenetic modifications of the OPRK1 or PDYN genes during the addiction cycle. Pharmacotherapeutic approaches limiting changes in KOPr/dynorphin tone, especially with KOPr partial agonists, may hold potential for the treatment of specific drug addictions and psychiatric comorbidity.

[1]  T. Miyata,et al.  Isolation and structural organization of the human preproenkephalin B gene , 1982, Nature.

[2]  Aashish Manglik,et al.  Structure of the δ-opioid receptor bound to naltrindole , 2012, Nature.

[3]  D S Rae,et al.  Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. , 1990, JAMA.

[4]  M. Munafo,et al.  Breaking Barriers in the Genomics and Pharmacogenetics of Drug Addiction , 2010, Clinical pharmacology and therapeutics.

[5]  James L. Howard,et al.  Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats , 2005, Psychopharmacology.

[6]  K. Lovell,et al.  Synthesis of neoclerodane diterpenes and their pharmacological effects. , 2011, Topics in current chemistry.

[7]  H. Emrich,et al.  Psychotomimesis mediated by kappa opiate receptors , 1986, Science.

[8]  J. Ott,et al.  Association of polymorphisms of the mu opioid receptor gene with the severity of HIV infection and response to HIV treatment. , 2012, The Journal of infectious diseases.

[9]  G. Koob,et al.  Stress modulation of drug self-administration: Implications for addiction comorbidity with post-traumatic stress disorder , 2012, Neuropharmacology.

[10]  R. Spanagel,et al.  Endogenous κ-opioid systems in opiate withdrawal: role in aversion and accompanying changes in mesolimbic dopamine release , 1994, Psychopharmacology.

[11]  Robert F. Dannals,et al.  Increased mu opioid receptor binding detected by PET in cocaine–dependent men is associated with cocaine craving , 1996, Nature Medicine.

[12]  J. Bidlack,et al.  Syntheses of novel high affinity ligands for opioid receptors. , 2009, Bioorganic & medicinal chemistry letters.

[13]  S. Strickland,et al.  Tissue plasminogen activator modulates the cellular and behavioral response to cocaine , 2009, Proceedings of the National Academy of Sciences.

[14]  V. Yuferov,et al.  Regulation of kappa opioid receptor mRNA in the rat brain by "binge' pattern cocaine administration and correlation with preprodynorphin mRNA. , 1996, Brain research. Molecular brain research.

[15]  L. Bierut,et al.  Association of the κ-opioid system with alcohol dependence , 2006, Molecular Psychiatry.

[16]  S. D. Glick,et al.  Kappa opioid inhibition of morphine and cocaine self-administration in rats , 1995, Brain Research.

[17]  O. Levran,et al.  Regional mRNA expression of the endogenous opioid and dopaminergic systems in brains of C57BL/6J and 129P3/J mice: Strain and heroin effects , 2011, Pharmacology Biochemistry and Behavior.

[18]  M. Kreek,et al.  Chronic cocaine alters brain mu opioid receptors , 1992, Brain Research.

[19]  J. V. Aldrich,et al.  Reinstatement of cocaine place-conditioning prevented by the peptide kappa-opioid receptor antagonist arodyn. , 2007, European journal of pharmacology.

[20]  M. Kreek,et al.  'Binge' cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen. , 1993, Brain research. Molecular brain research.

[21]  S. Watson,et al.  Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies. , 2007, European journal of pharmacology.

[22]  G F Koob,et al.  Transition from moderate to excessive drug intake: change in hedonic set point. , 1998, Science.

[23]  E. Butelman,et al.  Effect of the endogenous κ opioid agonist dynorphin A(1–17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice , 2004, Psychopharmacology.

[24]  G. Bakalkin,et al.  Prodynorphin CpG‐SNPs associated with alcohol dependence: elevated methylation in the brain of human alcoholics , 2011, Addiction biology.

[25]  E. Butelman,et al.  Effect of the κ opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice , 2004, Psychopharmacology.

[26]  H. Tejeda,et al.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders , 2011, Cellular and Molecular Life Sciences.

[27]  M. Kreek,et al.  Acute withdrawal from chronic escalating-dose binge cocaine administration alters kappa opioid receptor stimulation of [ 35 S] guanosine 5′-O-[gamma-thio]triphosphate acid binding in the rat ventral tegmental area , 2010, Neuroscience.

[28]  Bryan L. Roth,et al.  Structure of the human kappa opioid receptor in complex with JDTic , 2012, Nature.

[29]  W. Solecki,et al.  Forebrain PENK and PDYN gene expression levels in three inbred strains of mice and their relationship to genotype-dependent morphine reward sensitivity , 2010, Psychopharmacology.

[30]  M. Iyo,et al.  Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence , 2006, Neuroscience Letters.

[31]  J. Bidlack,et al.  Nalmefene Induced Elevation in Serum Prolactin in Normal Human Volunteers: Partial Kappa Opioid Agonist Activity? , 2005, Neuropsychopharmacology.

[32]  N. Mello,et al.  Effects of kappa opioids on cocaine self-administration by rhesus monkeys. , 1997, The Journal of pharmacology and experimental therapeutics.

[33]  J. Ott,et al.  Genetic susceptibility to heroin addiction: a candidate gene association study , 2008, Genes, brain, and behavior.

[34]  Julia C. Lemos,et al.  The Dysphoric Component of Stress Is Encoded by Activation of the Dynorphin κ-Opioid System , 2008, The Journal of Neuroscience.

[35]  P. Voorn,et al.  Delayed occurrence of enhanced striatal preprodynorphin gene expression in behaviorally sensitized rats: differential long-term effects of intermittent and chronic morphine administration , 1996, Neuroscience.

[36]  J. Frost,et al.  Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence , 2004, Biological Psychiatry.

[37]  M. Kreek,et al.  Pharmacogenetics and Human Molecular Genetics of Opiate and Cocaine Addictions and Their Treatments , 2005, Pharmacological Reviews.

[38]  M. Bruchas,et al.  The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors , 2010, Brain Research.

[39]  L. Pardo,et al.  Crystal structure of the μ-opioid receptor bound to a morphinan antagonist , 2012, Nature.

[40]  E. Butelman,et al.  Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors , 2005, Psychopharmacology.

[41]  G. Bigelow,et al.  Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans. , 2001, The Journal of pharmacology and experimental therapeutics.

[42]  G. Di Chiara,et al.  Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. , 1988, The Journal of pharmacology and experimental therapeutics.

[43]  G. Koob,et al.  The role of the dynorphin–κ opioid system in the reinforcing effects of drugs of abuse , 2010, Psychopharmacology.

[44]  J. Bidlack,et al.  Partial Opioids: Medications for the Treatment of Pain and Drug Abuse , 2000, Annals of the New York Academy of Sciences.

[45]  V. Yuferov,et al.  Cell‐specific effects of variants of the 68‐base pair tandem repeat on prodynorphin gene promoter activity , 2011, Addiction biology.

[46]  T. Robbins,et al.  Neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction , 2008, Philosophical Transactions of the Royal Society B: Biological Sciences.

[47]  D. Oslin,et al.  Confirmation of the association between a polymorphism in the promoter region of the prodynorphin gene and cocaine dependence , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[48]  L. Hood,et al.  Dynorphin-(1-13), an extraordinarily potent opioid peptide. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Woods,et al.  Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on κ-opioid agonists in the mouse writhing assay , 1994, Psychopharmacology.

[50]  M. Ko,et al.  Ultra-long antagonism of kappa opioid agonist-induced diuresis by intracisternal nor-binaltorphimine in monkeys , 2003, Brain Research.

[51]  Bryan L. Roth,et al.  Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Rainer Spanagel,et al.  Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway , 1992 .

[53]  H. Loh,et al.  Retinoic Acid-Induced Chromatin Remodeling of Mouse κ Opioid Receptor Gene , 2005, The Journal of Neuroscience.

[54]  S. Morgello,et al.  Tissue-specific DNA methylation of the human prodynorphin gene in post-mortem brain tissues and PBMCs , 2010, Pharmacogenetics and genomics.

[55]  J. Gelernter,et al.  The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk , 2008, Molecular Psychiatry.

[56]  T. Shippenberg,et al.  U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking , 1999, Psychopharmacology.

[57]  J. Franck,et al.  Ethanol alters the effect of kappa receptor ligands on dopamine release in the nucleus accumbens , 2007, Physiology & Behavior.

[58]  J. Ott,et al.  Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden , 2004, Molecular Psychiatry.

[59]  J. Sweeney,et al.  Psychiatric comorbidity in methadone maintained patients. , 1998, Journal of addictive diseases.

[60]  B. Cohen,et al.  Duration of Action of a Broad Range of Selective κ-Opioid Receptor Antagonists Is Positively Correlated with c-Jun N-Terminal Kinase-1 Activation , 2011, Molecular Pharmacology.

[61]  G. Aghajanian,et al.  Role of cAMP Response Element-Binding Protein in the Rat Locus Ceruleus: Regulation of Neuronal Activity and Opiate Withdrawal Behaviors , 2006, The Journal of Neuroscience.

[62]  E. Meloni,et al.  Kappa Opioid Receptor Signaling in the Basolateral Amygdala Regulates Conditioned Fear and Anxiety in Rats , 2011, Biological Psychiatry.

[63]  M. Kreek,et al.  Methadone‐Related Opioid Agonist Pharmacotherapy for Heroin Addiction: History, Recent Molecular and Neurochemical Research and Future in Mainstream Medicine , 2000, Annals of the New York Academy of Sciences.

[64]  Masaaki Iwata,et al.  Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant‐like effects , 2004, Journal of neurochemistry.

[65]  M. Heilig,et al.  1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial , 2003, The Lancet.

[66]  Jean Logan,et al.  Brain DA D2 receptors predict reinforcing effects of stimulants in humans: Replication study , 2002, Synapse.

[67]  E Rauch,et al.  An Allelic Variation in the Human Prodynorphin Gene Promoter Alters Stimulus‐Induced Expression , 2000, Journal of neurochemistry.

[68]  J. Ott,et al.  GENETIC STUDY: Prodynorphin gene promoter repeat associated with cocaine/alcohol codependence , 2007, Addiction biology.

[69]  Yuying Xie,et al.  Effect of μ-Opioid Receptor Gene Polymorphisms on Heroin-Induced Subjective Responses in a Chinese Population , 2007, Biological Psychiatry.

[70]  M. Nader,et al.  Temporal upregulation of prodynorphin mRNA in the primate striatum after cocaine self‐administration , 2003, The European journal of neuroscience.

[71]  M. Kreek,et al.  The frequency of cocaine administration impacts cocaine-induced receptor alterations , 2001, Brain Research.

[72]  Cécile Béguin,et al.  Depressive-Like Effects of the κ-Opioid Receptor Agonist Salvinorin A on Behavior and Neurochemistry in Rats , 2006, Journal of Pharmacology and Experimental Therapeutics.

[73]  J. Li,et al.  Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands. , 1997, The Journal of pharmacology and experimental therapeutics.

[74]  M. Kreek,et al.  Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. , 1994, Neuroreport.

[75]  M. Kreek,et al.  Predictable individual differences in the initiation of cocaine self-administration by rats under extended-access conditions are dose-dependent , 2001, Psychopharmacology.

[76]  M. Kreek,et al.  Downregulation of kappa-opioid receptors in basolateral amygdala and septum of rats withdrawn for 14 days from an escalating dose "binge" cocaine administration paradigm. , 2007, Synapse.

[77]  Anna B. Rachlin,et al.  Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats , 2012, Neuropharmacology.

[78]  J. Daunais,et al.  Cocaine self-administration increases preprodynorphin, but not c-fos, mRNA in rat striatum. , 1993, Neuroreport.

[79]  Yan Zhou,et al.  Differential gene expression in the rat caudate putamen after “binge” cocaine administration: Advantage of triplicate microarray analysis , 2003, Synapse.

[80]  J. Ott,et al.  Genotype patterns that contribute to increased risk for or protection from developing heroin addiction , 2008, Molecular Psychiatry.

[81]  K. Anastos,et al.  A C17T polymorphism in the mu opiate receptor is associated with quantitative measures of drug use in African American women , 2012, Addiction biology.

[82]  Bin Zhang,et al.  Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors. , 2011, Bioorganic & medicinal chemistry.

[83]  G. Wray,et al.  Multiple Functional Variants in cis Modulate PDYN Expression. , 2010, Molecular biology and evolution.

[84]  H. Akil,et al.  κ1 Receptor mRNA Distribution in the Rat CNS: Comparison to κ Receptor Binding and Prodynorphin mRNA , 1994, Molecular and Cellular Neuroscience.

[85]  G. Bakalkin,et al.  Prodynorphin promoter SNP associated with alcohol dependence forms noncanonical AP-1 binding site that may influence gene expression in human brain , 2011, Brain Research.

[86]  S. Higgins,et al.  The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review. , 2011, Drug and alcohol dependence.

[87]  H. Loh,et al.  Epigenetic regulation of kappa opioid receptor gene in neuronal differentiation , 2008, Neuroscience.

[88]  S. Nishiyama,et al.  Effects of Binge Pattern Cocaine Administration on Dopamine D1 and D2 Receptors in the Rat Brain: AnIn Vivo Study Using Positron Emission Tomography , 1996, The Journal of Neuroscience.

[89]  H. Akil,et al.  The cloned μ, δ and κ receptors and their endogenous ligands: Evidence for two opioid peptide recognition cores , 1995, Brain Research.

[90]  E. Butelman,et al.  Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction , 2005, Nature Neuroscience.

[91]  A. Markou,et al.  Neural substrates of psychostimulant withdrawal-induced anhedonia. , 2010, Current topics in behavioral neurosciences.

[92]  E. Butelman,et al.  Pharmacotherapy of addictions , 2002, Nature Reviews Drug Discovery.

[93]  Y. Shaham,et al.  Neurobiology of the incubation of drug craving , 2011, Trends in Neurosciences.

[94]  Andrew D. Johnson,et al.  Allelic Expression Imbalance of Human mu Opioid Receptor (OPRM1) Caused by Variant A118G* , 2005, Journal of Biological Chemistry.

[95]  H. Akil,et al.  Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor. , 1999, The Journal of pharmacology and experimental therapeutics.

[96]  Tao Li,et al.  GENETIC STUDY: An association of prodynorphin polymorphisms and opioid dependence in females in a Chinese population , 2009, Addiction biology.

[97]  V. Chefer,et al.  Quantitative no-net-flux microdialysis permits detection of increases and decreases in dopamine uptake in mouse nucleus accumbens , 2006, Journal of Neuroscience Methods.

[98]  J. Ott,et al.  A Functional Haplotype Implicated in Vulnerability to Develop Cocaine Dependence is Associated with Reduced PDYN Expression in Human Brain , 2009, Neuropsychopharmacology.

[99]  B. Bloch,et al.  kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[100]  H. Tennen,et al.  Validity of the SCID in substance abuse patients. , 1996, Addiction.

[101]  T. Shippenberg,et al.  κ-Opioid receptor modulation of accumbal dopamine concentration during operant ethanol self-administration , 2006, Neuropharmacology.

[102]  N. Hiroi,et al.  Regulation of cocaine reward by CREB. , 1998, Science.

[103]  J. Ott,et al.  Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction. , 2004, Pharmacogenetics.

[104]  J. Ott,et al.  Increased Attributable Risk Related to a Functional μ-Opioid Receptor Gene Polymorphism in Association with Alcohol Dependence in Central Sweden , 2005, Neuropsychopharmacology.

[105]  M. Gold,et al.  Efficacy of clonidine in opiate withdrawal: a study of thirty patients. , 1980, Drug and alcohol dependence.

[106]  Anne W. Schmidt,et al.  Pharmacological Characterization of 2-Methyl-N-((2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a High-Affinity Antagonist Selective for κ-Opioid Receptors , 2011, Journal of Pharmacology and Experimental Therapeutics.

[107]  M. Kreek,et al.  Acute intermittent morphine increases preprodynorphin and kappa opioid receptor mRNA levels in the rat brain. , 1999, Brain research. Molecular brain research.

[108]  Jun Wang,et al.  A regulatory variation in OPRK1, the gene encoding the κ-opioid receptor, is associated with alcohol dependence , 2008, Human molecular genetics.